☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
t2d
AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for the Treatment of Chronic Kidney Disease in Patients with and with...
August 9, 2021
Novo Nordisk Receives the US FDA's Refusal to File Letter for Semaglutide to Treat T2D
March 23, 2021
Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D
January 13, 2021
Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D
January 13, 2021
Novo Nordisk Reports Submission of Label Extension Application to the EMA for Semaglutide (once weekly- 2.0 mg) for T2D
December 30, 2020
Bayer Reports Regulatory Submission of Finerenone (BAY 94-8862) to the US and EU for CKD and T2D
November 10, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.